Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04868838 · ClinicalTrials.gov registry record · Phase 2

Daratumumab to Treat Active Lupus Nephritis

A Phase 2 study of Lupus Nephritis, sponsored by Mayo Clinic.

Active
Registry status
Phase 2
Development phase
12
Enrollment target
1
Study location

NCT04868838: Active Phase 2 study of Lupus Nephritis, sponsored by Mayo Clinic.

NCT04868838 is a Phase 2 study of Lupus Nephritis that is active but no longer recruiting, run by Mayo Clinic. The registered enrollment target is 12 participants, below the 310-participant average among 30 other Lupus Nephritis trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04868838, a Phase 2 study of Lupus Nephritis, is active but no longer recruiting, sponsored by Mayo Clinic.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
12 participants
Enrollment target
1
Study location

Study Summary

The purpose of this research is to study the safety and efficacy of daratumumab in inducing complete or partial remission in patients with active lupus nephritis.

Primary Outcome

Complete Renal Response:- \< 500 mg proteinuria/24 hours, Inactive urinary sediment (\<10 RBC/HPF and absence of RBC casts), No greater than a 15% reduction in eGFR from enrollment

Conditions Studied

Lupus Nephritis

Interventions

  • DRUG Daratumumab

Study Locations (1)

Minnesota

  • Mayo Clinic in Rochester - Rochester

Trial Details

FieldValue
Enrollment Target 12 participants
Start Date 2021-04-20
Est. Completion 2026-09
Phase Phase 2
Mayo Clinic

2,844 total trials

What the registry record for NCT04868838 still lists

NCT04868838 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 310-participant average among 30 other Lupus Nephritis trials with a reported enrollment target (96% lower).

The record links to 1 condition, with Lupus Nephritis appearing as the primary indexed condition, and to 1 intervention - of which Daratumumab is the first listed.

NCT04868838 reports a single indexed study location in Minnesota.

Frequently Asked Questions

What is clinical trial NCT04868838 about?

NCT04868838 is a clinical study titled "Daratumumab to Treat Active Lupus Nephritis". The purpose of this research is to study the safety and efficacy of daratumumab in inducing complete or partial remission in patients with active lupus nephritis.

What is the current status of trial NCT04868838?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2021-04-20. Estimated completion is 2026-09.

What conditions does trial NCT04868838 study?

This clinical trial studies the following conditions: Lupus Nephritis.

What interventions are being tested in trial NCT04868838?

The interventions under investigation include: Daratumumab (DRUG).

Who is sponsoring clinical trial NCT04868838?

This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04868838 being conducted?

This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Lupus Nephritis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04868838's enrollment target sits among peer trials

12 29th of 30 higher than 2 of 30 other Lupus Nephritis trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Lupus Nephritis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02602769 · 12 participants

    Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome

  • NCT02605421 · 12 participants · Phase 2

    Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma

  • NCT02619448 · 12 participants · Early Phase 1

    Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC

  • NCT03311503 · 12 participants · Phase 1

    Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT04868838, the US trial registry maintained by the National Library of Medicine. NCT04868838 (small enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.